Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on track
PALISADE-3 trial initiation anticipated in 1H 2024; PALISADE-4 trial initiation anticipated in 2H 2024
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$VTGN #mentalhealth—Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update.
“Momentum from clinical and corporate milestones achieved through the end of last quarter have significantly advanced our efforts to develop and commercialize fasedienol as a potential first-in-class acute treatment for adults with social anxiety disorder. Building on the positive results of our PALISADE-2 Phase 3 trial in SAD, we remain on track to initiate our PALISADE-3 Phase 3 trial in SAD during the first half of this year,” said Shawn Singh, Chief Executive Officer of Vistagen. “In parallel, we continue to make significant progress toward Phase 2B development of two additional clinical-stage neuroscience assets in our pipeline, itruvone for major depressive disorder and hormone-free PH80 for women’s health indications, including vasomotor symptoms (hot flashes) due to menopause.”
Fasedienol Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)
To complement Vistagen’s successful PALISADE-2 Phase 3 trial of fasedienol for the acute treatment of SAD, the Company’s PALISADE-3 trial, anticipated to initiate during the first half of 2024, as well as its PALISADE-4 trial, which is anticipated to be initiated in the second half of 2024, will be U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 trials designed to evaluate the efficacy, safety, and tolerability of the acute administration of fasedienol to relieve anxiety symptoms in adult patients with SAD, after administration of a single dose of fasedienol during a public speaking challenge in a clinical setting, as measured using the patient-reported Subjective Units of Distress Scale (SUDS) as the primary efficacy endpoint.
Vistagen believes either PALISADE-3 or PALISADE-4, if successful, together with the positive results from PALISADE-2, may establish substantial evidence of the effectiveness of fasedienol in support of a potential fasedienol U.S. New Drug Application (NDA) submission for the acute treatment of anxiety in adults with SAD.
Itruvone Nasal Spray for Major Depressive Disorder (MDD)
Leveraging a successful exploratory Phase 2A trial of itruvone for the treatment of MDD, preparations and planning are underway for Phase 2B development.
PH80 Nasal Spray for Vasomotor Symptoms (Hot Flashes) due to Menopause and other Women’s Health Indications
Expanding upon successful exploratory Phase 2A trials of PH80 in two women’s health indications, preparations and planning are underway for U.S. IND-enabling nonclinical studies to facilitate U.S. Phase 2B development of hormone-free PH80 for the treatment of vasomotor symptoms (hot flashes) due to menopause and, potentially, premenstrual dysphoric disorder (PMDD).
Fiscal Year 2024 Third Quarter Financial Results
Research and development (R&D) expense: R&D expense was $4.5 million and $6.9 million for the three months ended December 31, 2023 and 2022, respectively. The decrease in R&D expense was primarily due to a decrease in clinical and development expenses related to the timing of expenses incurred for the Company’s Phase 3 trials of fasedienol in SAD.
General and administrative (G&A) expense: G&A expense was $3.8 million and $3.1 million for the three months ended December 31, 2023 and 2022, respectively. The increase was primarily due to increases in compensation and related expenses.
Net loss: Net loss was $6.3 million and $9.8 million for the three months ended December 31, 2023, and 2022, respectively.
Cash position: At December 31, 2023, the Company had cash and cash equivalents of approximately $126.6 million.
As of February 12, 2024, the Company had 27,029,731 shares of common stock issued and 3,577,240 pre-funded warrants outstanding.
Conference Call:
Vistagen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update.
U.S. Dial-in (Toll-Free): 1-877-407-9716
International Dial-in Number (Toll): 1-201-493-6779
Conference ID: 13743176
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1648110&tp_key=097d964c22
A live audio conference call webcast will also be available via the above link. Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately 8:00 p.m. Eastern Time on Tuesday, February 13, 2024. To listen to the replay, call toll-free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll). Please use the replay access ID number: 13743176.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders. Five of Vistagen’s six clinical-stage product candidates belong to a new class of drugs known as pherines, which have the potential to rapidly deliver meaningful efficacy with a differentiated safety profile. Pherines are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuits in the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen’s sixth clinical-stage product candidate, AV-101, is an investigational oral drug candidate with the potential to inhibit, but not block, NMDA receptor activity. Vistagen is passionate about transforming what is possible in the treatment of anxiety, depression, and other neuroscience disorders. Connect at www.Vistagen.com.
Forward-looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. As with all pharmaceutical products, there are substantial risks and uncertainties in the process of development and commercialization and actual results or developments may differ materially from those projected or implied in these forward-looking statements. Among other things, there can be no guarantee that any of the Company’s drug candidates will successfully complete ongoing or, if initiated, future clinical trials, receive regulatory approval or be commercially successful, or that the Company will be able to successfully replicate the result of past studies of its product candidates, including fasedienol, itruvone, PH80 or its other drug candidates. Other factors that may cause such a difference include, without limitation, risks and uncertainties relating to the Company’s submission of an U.S. NDA to the FDA for any product candidate, including fasedienol; the ability of any clinical trial information submitted by the Company to the FDA to support an U.S. NDA; other risks and uncertainties related to delays in launching, conducting and/or completing ongoing and planned clinical trials, including PALISADE-3 and PALISADE-4 or additional Phase 2 clinical trials of itruvone or PH80; the scope and enforceability of the Company’s patents, including patents related to the Company’s pherine drug candidates and AV-101; fluctuating costs of materials and other resources and services required to conduct the Company’s ongoing and/or planned clinical and non-clinical trials; market conditions; the impact of general economic, industry or political conditions in the United States or internationally; and other technical and unexpected hurdles in the development, manufacture and commercialization of the Company’s product candidates. These risks are more fully discussed in the section entitled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended March 31, 2023, and in the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2023, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the U.S. Securities and Exchange Commission (SEC). The Company’s SEC filings are available on the SEC’s website at www.sec.gov. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.
| VISTAGEN THERAPEUTICS, INC. | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
|
|
|||||||
| December 31, | March 31, | ||||||
|
2023 |
2023 |
||||||
| (Unaudited) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents |
$ |
126,559,200 |
|
$ |
16,637,600 |
|
|
| Prepaid expenses and other current assets |
|
1,480,300 |
|
|
802,700 |
|
|
| Deferred contract acquisition costs – current portion |
|
74,500 |
|
|
67,100 |
|
|
| Total current assets |
|
128,114,000 |
|
|
17,507,400 |
|
|
| Property and equipment, net |
|
445,100 |
|
|
507,300 |
|
|
| Right-of-use asset – operating lease |
|
1,933,600 |
|
|
2,260,300 |
|
|
| Deferred offering costs |
|
325,700 |
|
|
495,700 |
|
|
| Deferred contract acquisition costs – non-current portion |
|
148,700 |
|
|
217,600 |
|
|
| Security deposits |
|
100,900 |
|
|
100,900 |
|
|
| Total assets |
$ |
131,068,000 |
|
$ |
21,089,200 |
|
|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable |
$ |
1,737,000 |
|
$ |
2,473,100 |
|
|
| Accrued expenses |
|
129,300 |
|
|
787,400 |
|
|
| Note payable |
|
– |
|
|
105,300 |
|
|
| Deferred revenue – current portion |
|
1,762,800 |
|
|
714,300 |
|
|
| Operating lease obligation – current portion |
|
533,500 |
|
|
485,600 |
|
|
| Financing lease obligation – current portion |
|
1,900 |
|
|
1,700 |
|
|
| Total current liabilities |
|
4,164,500 |
|
|
4,567,400 |
|
|
| Deferred revenue – non-current portion |
|
1,899,400 |
|
|
2,314,600 |
|
|
| Operating lease obligation – non-current portion |
|
1,713,300 |
|
|
2,119,800 |
|
|
| Financing lease obligation – non-current portion |
|
6,000 |
|
|
7,400 |
|
|
| Total liabilities |
|
7,783,200 |
|
|
9,009,200 |
|
|
| Commitments and contingencies (Note 10) | |||||||
| Stockholders’ equity: | |||||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2023 and March 31, 2023; no shares outstanding at December 31, 2023 and March 31, 2023 |
|
– |
|
|
– |
|
|
| Common stock, $0.001 par value; 325,000,000 shares authorized at December 31, 2023 and March 31, 2023; 27,029,731 and 7,315,583 shares issued at December 31, 2023 and March 31, 2023, respectively |
|
27,000 |
|
|
7,300 |
|
|
| Additional paid-in capital |
|
473,918,200 |
|
|
342,892,500 |
|
|
| Treasury stock, at cost, 4,522 shares of common stock held at December 31, 2023 and March 31, 2023 |
|
(3,968,100 |
) |
|
(3,968,100 |
) |
|
| Accumulated deficit |
|
(346,692,300 |
) |
|
(326,851,700 |
) |
|
| Total stockholders’ equity |
|
123,284,800 |
|
|
12,080,000 |
|
|
| Total liabilities and stockholders’ equity |
$ |
131,068,000 |
|
$ |
21,089,200 |
|
|
| VISTAGEN THERAPEUTICS | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS | |||||||||||||||
| (Unaudited) | |||||||||||||||
|
|
|||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| December 31, | December 31, | ||||||||||||||
|
2023 |
2022 |
2023 |
2022 |
||||||||||||
| Revenues: | |||||||||||||||
| Sublicense and other revenue |
$ |
411,400 |
|
$ |
179,600 |
|
$ |
866,700 |
|
$ |
(402,900 |
) |
|||
| Total revenues |
|
411,400 |
|
|
179,600 |
|
|
866,700 |
|
|
(402,900 |
) |
|||
| Operating expenses: | |||||||||||||||
| Research and development |
|
4,537,600 |
|
|
6,854,000 |
|
|
12,585,400 |
|
|
35,039,800 |
|
|||
| General and administrative |
|
3,757,800 |
|
|
3,092,100 |
|
|
9,943,300 |
|
|
11,586,200 |
|
|||
| Total operating expenses |
|
8,295,400 |
|
|
9,946,100 |
|
|
22,528,700 |
|
|
46,626,000 |
|
|||
| Loss from operations |
|
(7,884,000 |
) |
|
(9,766,500 |
) |
|
(21,662,000 |
) |
|
(47,028,900 |
) |
|||
| Other income, net: | |||||||||||||||
| Interest income, net |
|
1,534,200 |
|
|
5,300 |
|
|
1,823,900 |
|
|
13,700 |
|
|||
| Loss before income taxes |
|
(6,349,800 |
) |
|
(9,761,200 |
) |
|
(19,838,100 |
) |
|
(47,015,200 |
) |
|||
| Income taxes |
|
– |
|
|
– |
|
|
(2,500 |
) |
|
(5,500 |
) |
|||
| Net loss and comprehensive loss |
$ |
(6,349,800 |
) |
$ |
(9,761,200 |
) |
$ |
(19,840,600 |
) |
$ |
(47,020,700 |
) |
|||
| Basic and diluted net loss per common share |
$ |
(0.22 |
) |
$ |
(1.42 |
) |
$ |
(1.27 |
) |
$ |
(6.82 |
) |
|||
| Weighted average common shares outstanding, basic and diluted |
|
29,388,085 |
|
|
6,894,603 |
|
|
15,632,451 |
|
|
6,891,641 |
|
|||
Contacts
Investors Inquiries:
Mark A. McPartland
(650) 577-3606
markmcp@vistagen.com
Media Inquiries:
Caren Scannell
(650) 577-3601
cscannell@vistagen.com